Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
NVO News
Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to DKK 550 from DKK 600 and keeps an Equal Weight rating on the...
Pharmaceutical stocks initially fell worldwide after President Donald Trump said he plans to sign an executive order to lower U.S. prescription drug prices by m...
Pharma stocks under pressure as Trump plans executive order to lower drug prices The Trump administration is definitely on a low prices kick this morning (or a...
Analyst ratings
62%
of 34 ratingsMore NVO News
Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top....
Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO) Wegovy (semaglutide) in a Phase 3...
On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the “most consequential executive order” in U.S. history, aimed...
Preview in new tab Pharmaceutical giants Eli Lilly (LLY) and Novo Nordisk (NVO) are engaged in a head-to-head battle to prove their supremacy in the multi-bill...
An update from Novo Nordisk ( (NVO) ) is now available. On May 7, 2025, Novo Nordisk disclosed transactions involving the sale of 40,000 shares by board member...
Novo Nordisk A/S NVO is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and...
Novo Nordisk ((NVO)) has held its Q1 earnings call. Read on for the main highlights of the call. Novo Nordisk’s recent earnings call painted a picture of robus...